Related Experiment Videos
[Treatment of hypercalciuria found in urolithiasis patients]
Insights
Hydrochlorothiazide effectively reduces urinary calcium excretion in hypercalciuria patients. While generally safe, it can lower potassium and raise uric acid levels, requiring further study for long-term use.
Area of Science:
- Nephrology
- Pharmacology
Context:
- Hypercalciuria is a condition characterized by elevated calcium levels in the urine.
- Managing hypercalciuria is crucial for preventing kidney stones and bone disease.
Purpose:
- To evaluate the efficacy and safety of hydrochlorothiazide in reducing urinary calcium excretion in patients with hypercalciuria.
Summary:
- Hydrochlorothiazide (50 mg/day) significantly decreased urinary calcium after 4 weeks in 35 hypercalciuria patients.
- No significant changes in urinary magnesium were observed, but the magnesium-calcium ratio increased.
- Adverse effects included significant decreases in serum potassium and increases in serum uric acid, though no serious side effects were reported.
Impact:
- Hydrochlorothiazide demonstrates potential as a safe and effective treatment for reducing urinary calcium.
- Further research is needed to determine optimal long-term dosing and administration strategies.
Abstract:
To reduce urinary calcium excretion, 50 mg of hydrochlorothiazide per day was given to 35 patients with hypercalciuria. Urinary calcium decreased significantly after 4 weeks of drug administration, but urinary magnesium did not change. Magnesium calcium ratio increased significantly. Although serious side effects were not seen, serum potassium decreased and serum uric acid increased significantly. From these results thiazide seems to be a useful and safe medicine to reduce urinary calcium excretion. The dose and method of administration require further examination because the patients have to take the drug for a long time.